Metastatic castration-resistant prostate cancer remains andr

[Admin]

Metastatic castration-resistant prostate cancer remains androgen-driven 06/05/2011

0 Comments

The success of the recent trials with Zytiga don't just give hope in themselves.

They do show what many have suspected, but has not been proven until now:

"metastatic castration-resistant prostate cancer remains androgen-driven"

If you missed the latest report:

"active treatment [jm] was found to reduce the risk of death by 35%, compared with placebo. Mortality was 42% with active treatment, compared with 55% with placebo. Median overall survival was 14.8 months with abiraterone, compared with 10.9 months with placebo"

I am not a doctor.

Find the original article by searching Google for

abiraterone "may 26" new england journal of medicine